Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of a new startup company CombineAble.AI, which will speed up the development of therapeutics by addressing challenges associated with antibody design.
CombinAble.AI was formed following an AION Labs startup challenge aimed at developing an AI-based solution for...
Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of a new startup, TenAces.
TenAces will utilize AI, integrating biology and machine learning algorithms, to discover molecular glue therapies to enhance targeted protein degradation.
Molecular glues are protein-binding small molecules that change two protein...
Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of its second startup, DenovAI.
DenovAI will develop an AI-enabled computational biophysics platform that can discover potential antibodies directed toward specific epitopes (the part of an antigen molecule recognized by the immune system to which an antibody attaches...
This week Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies like AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services, announced the formation of a new startup company dubbed OMEC.AI.
OMEC.AI aims to build a computational platform using AI that can help researchers assess the clinical trial readiness of a drug...
Artificial intelligence could potentially disrupt nearly every industry. Pharma giants have continued to take note. From AI in drug discovery to digital therapeutics, big name life science companies have invested time and money into the space.
However, big tech's move fast and break things mentality doesn't always align with pharma's regulated model. Today a number of accelerators and labs are...
_96381.jpg)
